Peptide Cancer Vaccine Market– Introduction
In medical terminology, Peptides are short chain of amino acids connected by peptide bonds. Cancer peptide vaccines are promising cancer immunotherapy that are induced in cancer-specific cytotoxic T lymphocytes (CTLs) tumors to control and eradicate cancer cells from growing.
Peptide based synthetic vaccines also alluded to as epitope vaccines are the subunit made from peptides. These peptides replicate the epitopes of the antigen that activates direct or potent immune responses. Peptide vaccines not only induce protection against transmissible pathogens and non-infectious diseases but also can be used as therapeutic cancer vaccines where the peptides from the tumor-associated antigens are used to induce an effective anti-tumor T-cell response. The practice of peptide cancer vaccine is to control the tumor growth in laboratory mouse models for clinical results. Lately, the clinical trials performed using the vaccine showed negative results. The preparation and application of the vaccine is easy to synthesize, it is cost efficient and it is simple in application hence it is driving force.
Market Overview, Forecast, and Drivers
Peptide Cancer Vaccine Market is anticipated to show a convincing rise during the forecasted period.
Overall, the rapidly growing incidence and mortality rate is growing rapidly across the world. Reason being rising geriatric population and many other factors also contribute such as changing lifestyles of people, fluctuating environmental conditions, rising level of ultra violet rays causing skin cancers. In addition to this there is rise in people who smoke resulting to high number of lung cancer cases. This has resulted into the rise in need for cancer vaccinations.
Over past decades, immunotherapy has emerged to be one of the pillars in cancer treatment following surgery, chemotherapy and radiotherapy. Of all immunotherapies, the therapeutic cancer vaccine has the most interesting field attributable to their capacity to obtain explicit immune reaction to the growth of antigens. The vigorous research and development activities carried out in this sector have led to the development of cancer vaccines by using various elements including DNA, RNA, proteins that are extensively available for medical studies.
Peptide cancer vaccines provide various benefits such as easy synthesizing, cost effective, essential element in clinical practices, lowering risk factor of antigen-induced anaphylaxis and flexible while changing antigen. These factors are accountable for increasing the growth of the market.
Peptide Cancer Vaccine Market: Key Trends
Major Players Emphasize on the Research Activities to Develop Peptide Vaccine to grow the Market Demand
Peptide Cancer Vaccines have various advantages such as, they are easy to prepare, easy to synthesize, cost-effective, helpful in clinical practices, have lower risk of antigen-induced anaphylaxis, and are flexible in changing antigen. All these advantages are responsible for increasing the growth of Peptide Cancer Vaccine Market in coming years.
In addition, various key players are also investing in research activities to produce Peptide Cancer Vaccines because of their beneficial advantages. We can consider an example of, Boston Biomedical, Inc., which is a global developer of novel cancer therapeutics that announced the evaluation of DSP-7888, an investigational WT1 cancer peptide vaccine to investigate the safety, tolerability, and determination of the recommended phase 2 doses of DSP-7888 in patients.
Provision of Healthy Features of Peptide Vaccine than Conventional Therapies that drive the Market
The Peptide Cancer Vaccines have good features in terms of better safety and tolerance than conventional methods such as, immune checkpoint inhibitors and chemotherapy. The growing prevalence of cancer and presence of good characteristics of these vaccines are accelerating the demand for Peptide Cancer Vaccine Market during the given time period.
Request a Free Sample Copy: https://wemarketresearch.com/sample-request/peptide-cancer-vaccine-market/3/
Market Drivers & Restrictions
Vaccines are biological products that stimulate the immune system of the body against foreign elements. The stimulated immune system destroys the alien body and recalls it. Vaccines work on the principle of memorizing a foreign particle and prevents it from attacking the body in the future. Cancer vaccines are medicines are one such biological product. Owing to the fact of awareness about Peptide Cancer Vaccine against the treatment is increasing the market growth. Rising prevalence of cancer and failure of traditional methods twinning with rising demand for immunotherapy is fueling the market growth. As per the report by the National Cancer Institute in 2016, it was projected about 16 million new cases of cancer to be diagnosed with an approximate 595,690 deaths from the disease. Furthermore, the World Health Organization (WHO) stated approximately 14 million cases of cancer and 8.2 million deaths caused by the disease in 2012. Among these, the common cases were of lung, colorectal, prostate, cervical, and breast cancer which has led to significant rise in the market.
Market Key Players
The market is known by its investors or key players. Some prominent key players are
TapImmune, BrightPath, ISA Pharmaceuticals, Generex Biotechnology, Immatics, OncoTherapy Science, Enzo Life Science, Antigen Express, BioLife Science, Generex Biotechnology Corporation, Immatics Biotechnologies, Immune Design, Immunomedics, Galena Biopharma, Lytix Biopharma, Merck, and Ultimovacs, Biotherapeutics, Seals, Boston Biomedical, VAXON Biotech
segmentation
The Peptide Cancer Vaccine Market has been segmented into sections as on Product Type and Application
The Peptide Cancer Vaccine Market by Product Type is further segregated into:
- Personalized Peptide Vaccine
- Peptide-Pulsed Dendritic Cancer Vaccine
Among all types, the Personalized Peptide Vaccine segment is expected to dominate the market during and after the forecast time.
The Peptide Cancer Vaccine Market by Application is further divided into:
- breast cancer
- lung cancer
Peptide Cancer Vaccine Market Regional Outlook
Based on the geographical view, the market occupies regions like North America, South America, Europe, Asia Pacific, Middle East & Africa. Of all regions, North America was dominating the Peptide Cancer Vaccine Market during the forecast period.
Covid-19 impact on the market:
The emergence of Covid-19 pandemic and related confinement bars has a mixed effect on businesses worldwide and additionally on the health care service market. The initial wave of Covid-19 caused an unprecedented contraction in economic activity and a collapse of overall logistics, hence, the market is expected to show relatively slow growth. Many key players’ sale was impacted due to lockdowns and social distancing globally. The global pharma & healthcare market was severely impacted due to scarcity of drugs owing to consequent lockdowns.
Interested in purchasing this Report? click here https://wemarketresearch.com/purchase/peptide-cancer-vaccine-market/3/?license=single
About We Market Research
We Market Research is an established market analytics and research firm with a domain experience sprawling across different industries. We have been working on multi-county market studies right from our inception. Over the time, from our existence, we have gained laurels for our deep rooted market studies and insightful analysis of different markets.
Our strategic market analysis and capability to comprehend deep cultural, conceptual and social aspects of various tangled markets has helped us make a mark for ourselves in the industry. We Market Research is a frontrunner in helping numerous companies; both regional and international to successfully achieve their business goals based on our in-depth market analysis. Moreover, we are also capable of devising market strategies that ensure guaranteed customer bases for our clients.
